

Remarks

The following remarks are submitted to be fully responsive to the Official action mailed June 3, 2009. Claims 1-20 are pending in the application. Claims 1-20 are subject to restriction to one of the following groups as required by the Examiner:

Group I: Claims 1-12, drawn to a method for identifying and/or producing an effector of a calmodulin-dependent peptidyl-prolyl cis/trans isomerase;

Group II: claims 13-16, drawn a compound as a cycloheximide derivative;

Group III: claim 17, drawn to the effector with a pharmaceutically acceptable carrier or solvent;

Group IV: claim 18, drawn to a method for the treatment of tumor diseases;

Group V: claim 19, drawn to a method for the inhibition or attenuation of a transplant rejection or for the treatment of neurodegenerative diseases; or,

Group VI: claim 20, drawn to a kit.

Applicant hereby elects to prosecute Group I, directed to a method for identifying and/or producing an effector of a calmodulin-dependent peptidyl-prolyl cis/trans isomerase. This election is made without traverse.

In addition to the election above, the Office has required the Applicant to elect a single species from each type (A-E) to which the claims shall be restricted if no generic claim is finally held to be allowable.

- A. The type of CaMAP from among those instantly claimed – i.e., FKBP36, FKBP27.7, FKBP44, - see e.g., claim 4.
- B. The type of calmodulin or the calmodulin fragment/derivative from among those instantly claimed-i.e., CALM_ACHKL (P15094), CALM_BLAEM (Q9HFY6), etc.,-see, e.g., claim 5.
- C. The type of bivalent ions from among those instantly claimed-i.e., Zn^{2+} , Cu^{2+} , Co^{2+} , etc.,-see e.g. claim 6.

- D. The type of formula (1) from among those instantly claimed-i.e., grouped in (a)-(e) in claim 15.
- E. The type of compound from among those instantly claimed-i.e., listed as compound 1-39 in claim 16.

Since Applicant has elected the claims of Group I for prosecution, it is believed that the species requirement is directed to points A, B, and C as detailed in the Office action. To be fully responsive to the election of species requirement, Applicant hereby elects the following species:

- A. FKBP38 (Swiss-Prot FKB8 Human)
- B. P02593 (Human calmodulin)
- C. Ca²⁺ as the bivalent cation

Claims 1-12 read upon the elected species.

Conclusion

In view of the above election and remarks, it is respectfully submitted that the foregoing is fully responsive to the outstanding Official Action mailed June 3, 2009. In the event that a phone conference would help resolve any issues in the application, the Examiner is invited to contact the undersigned at the phone number below.

Respectfully Submitted,

Dated: 01 July 09

By: Paul L. Weaver

Paul L. Weaver, Reg. No. 48,640

Customer Number 33072

Phone: 651-275-9835

Fax: 651-351-2954